linagliptin and Hyperplasia

Neointima hyperplasia is the pathological basis of atherosclerosis and restenosis which have been associated with diabetes mellitus (DM). It is controversial for linagliptin and metformin to protect against vascular neointimal hyperplasia caused by DM. Given the combined therapy of linagliptin and metformin in clinical practice, we investigated whether the combination therapy inhibited neointimal hyperplasia in the carotid artery in diabetic rats.. We demonstrated that the potential protection of the combined use of linagliptin and metformin on VSMC remodeling through AMPK/Nox4 signal pathway, resulting in the improvement of neointima hyperplasia in diabetic rats. This study provided new therapeutic strategies for vascular stenosis associated with diabetes.

Topics: AMP-Activated Protein Kinases; Animals; Aorta, Thoracic; Carotid Arteries; Constriction, Pathologic; Diabetes Mellitus, Experimental; Endothelium, Vascular; Flow Cytometry; Hyperplasia; Linagliptin; Male; Metformin; Muscle, Smooth, Vascular; NADPH Oxidase 4; NADPH Oxidases; Neointima; Oxygen; Rats; Rats, Sprague-Dawley; RNA Interference; Signal Transduction; Vascular Remodeling; Vasoconstriction; Wound Healing